Reducing mortality from HIV infection and tuberculosis

The Lancet Infectious Diseases

Volumn 11, Issue 7, 2011, Pages 494-495

  Koole, Olivier ^a   Colebunders, Robert ^a,b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ALGORITHM; ANTIBIOTIC THERAPY; CD4 LYMPHOCYTE COUNT; CRITICALLY ILL PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MEDICAL PRACTICE; MORTALITY; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM SMEAR; SURVIVAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS;

ALGORITHMS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; HIV; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 79959308932     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70094-9     Document Type: Letter

References (13)

1. Hotlz TH, Kabera G, Mthiyane T, et al. Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011, published online April 21. 10.1016/S1473-3099(11)70057-3.
2. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings 2007, WHO, World Health Organization, Geneva, (accessed March 21, 2011). http://whqlibdoc.who.int/hq/2007/WHO_HTM_TB_2007.379_eng.pdf.
3. Koole O, Thai S, Khun KE, et al. Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS One 2011, 6:e18502.
4. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
5. Lawn SD, Ayles H, Egwaga S, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis 2011, 15:287-295.
6. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/μL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010, 51:448-455.
7. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision 2010, WHO, World Health Organization, Geneva, (accessed March 21, 2011). http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
8. Havlir DV, Ive P, Kendall M, et al. International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE study. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011. Abstr 38.
9. Abdool Karim SS, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011. Abstr 39LB.
10. Murphy RA, Sunpath H, Taha B, et al. Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010, 14:903-908.
11. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005, 19:2141-2148.
12. Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav 2010, published online April 30. 10.1007/s10461-010-9704-1.
13. Havlir DV, Getahun H, Sanne I, Nunn P Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008, 300:423-430.